Barclays PLC Cuts Position in Silence Therapeutics plc (NASDAQ:SLN)

Barclays PLC decreased its position in Silence Therapeutics plc (NASDAQ:SLN) by 40.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,333 shares of the company’s stock after selling 2,237 shares during the quarter. Barclays PLC’s holdings in Silence Therapeutics were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of SLN. Values First Advisors Inc. bought a new stake in shares of Silence Therapeutics in the 3rd quarter worth about $56,000. Quarry LP bought a new stake in Silence Therapeutics during the second quarter worth approximately $114,000. Verition Fund Management LLC purchased a new stake in Silence Therapeutics during the third quarter valued at approximately $207,000. The Manufacturers Life Insurance Company bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at approximately $318,000. Finally, Y Intercept Hong Kong Ltd lifted its stake in shares of Silence Therapeutics by 22.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock valued at $383,000 after purchasing an additional 3,923 shares during the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Chardan Capital restated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Monday, December 9th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Silence Therapeutics has a consensus rating of “Buy” and an average target price of $57.20.

Silence Therapeutics Stock Down 5.7 %

SLN opened at $6.34 on Friday. The company has a market cap of $189.74 million, a PE ratio of -4.04 and a beta of 1.08. Silence Therapeutics plc has a twelve month low of $5.81 and a twelve month high of $27.72. The company has a 50-day moving average price of $9.30 and a 200 day moving average price of $15.37.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.